Prosus has led a €480 million (US$550 million) funding round in European health and insurance tech company Alan, valuing the AI-native platform at €5.5 billion (US$6.3 billion). The investment, announced on 24 June 2026, will accelerate Alan's international expansion and the development of its AI-powered healthcare services that combine insurance, prevention and care delivery.
Prosus invested €400 million (US$460 million) in primary and secondary equity. Existing investors Teachers' Venture Growth and Index Ventures joined the round, along with new investor Dara Holdings. Alan reached more than €800 million in annual recurring revenue as of Q1 2026, up 53% year-on-year, and is profitable in France, its largest market. The company serves over 1.1 million individuals and has scaled with limited headcount growth, a sign of the efficiency gained from its AI-led model.
An AI-native health platform built for prevention
Alan has built an integrated platform where insurance, prevention and care delivery work together to create a personalised healthcare experience. The company's AI for Insurance and health services aims to shift healthcare from reactive treatment to proactive prevention. Professionals working with AI for Healthcare are seeing similar shifts in how technology can support clinical and administrative workflows. Alan's platform is designed for scale, with a cost-efficient delivery model that underpins its rapid growth.
"Healthcare presents one of the most significant global opportunities for AI-led transformation," said Fahd Beg, Head of Investments at Prosus Group. "Alan has built something unique: an integrated platform where insurance, prevention and care delivery reinforce each other, creating an exceptional healthcare experience for consumers and outstanding platform engagement. We're excited to partner with Alan to accelerate its international expansion and unlock value through our ecosystem."
What the Prosus partnership brings
The partnership will give Alan access to Prosus' Large Commerce Model to accelerate AI product development. Prosus will also support Alan's expansion into large international markets where Prosus already has a strong presence. In return, Alan will help Prosus extend its consumer ecosystem into healthcare and strengthen its life assistant strategy.
Jean-Charles Samuelian-Werve, co-founder and CEO of Alan, said: "Health can't wait, not for symptoms to get worse, not for a six-month appointment, not for the system to catch up. Yet that is exactly how healthcare works today. We believe great health is a universal right, and that prevention should be too. For ten years we have shown that technology can turn healthcare from reactive to proactive, helping people act early instead of reacting late. That is what prevention insurance is, and it's the category we are building. We selected Prosus for their very deep expertise in international expansion and consumer products and to benefit from the incredible ecosystem they are building. We are still at the very beginning of what Alan can become."
The closing of the financing round is subject to regulatory approvals from the relevant French financial authorities.
Why this matters for healthcare professionals
Alan's model shows that AI can integrate insurance and care delivery on a single platform, pushing the industry toward prevention over treatment. As platforms like Alan scale internationally, healthcare professionals may see new tools that automate administrative tasks, personalise patient engagement, and support earlier interventions. Efficiency gains from AI-native design could also influence hiring and team structures in health systems-fewer staff handling more patients through technology-assisted workflows. Professionals who understand how AI is reshaping both clinical care and insurance models will be better positioned as these platforms become more common.
Your membership also unlocks:
